FOLH1 and prostate carcinoma: Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) is currently recommended to stage Prostate Cancer (PCa) patients with recurrent disease and to select patients for metastasis-directed therapy (MDT).